Prof Min Kim, one of South Korea’s leading vitreoretinal surgeons, notes meaningful advantages in the new BIOM 6 viewing ...

Bausch + Lomb announced that CEO and director Brent Saunders left the company and its board on October 12, 2026. Board ...

Eyecare company Bausch + Lomb (NYSE:BLCO) exceeded in Q3 2026, with revenue up 7.3% year on year to $1.38 billion. The ...

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market open. Here’s what to expect.

Key TakeawaysBausch + Lomb shares jumped 16% after a third-quarter profit beat and raised full-year guidance. Profit is the story: adjusted EBITDA rose 34% on 7% revenue growth.

The eye-health company’s third-quarter net income came in at $32 million, or 9 cents a share, compared with a loss of $28 ...

Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end. He is stepping down immediately from the role – by mutual agreement with the board of directors – ...

Brent Saunders is stepping down as Bausch + Lomb’s CEO through mutual agreement with the company’s board, Bausch announced Monday. (Mike Coppola/Getty Images) Less than four years after returning to ...

Appio was appointed chairman of the Bausch + Lomb Board of Directors in August 2026. The Board believes Appio's deep knowledge of the business, global leadership experience and longstanding connection ...

Net Income Net income attributable to Bausch + Lomb Corporation for the third quarter of 2026 was $32 million, as compared to a $28 million loss for the third quarter of 2025, a favorable change of ...

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It ...

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading ...